Erythropoietin and Nonhematopoietic Effects.
Erythropoietin (EPO) is the main regulator of red blood cell production. Since the 1990s, EPO has been used for the treatment of anemia associated with end-stage renal failure and chemotherapy. The erythropoietin receptors were found on other organs such as the brain, spinal cord, heart and skin. In addition, it has been shown that many tissues produce and locally release EPO in response to hypoxic, biochemical and physical stress. In cellular, animal and clinical studies, EPO protects tissues from ischemia and reperfusion injury, has antiapoptotic effects and improves regeneration after injury. In this article, we mainly review the nonhematopoietic effects and new possible clinical indications for EPO.
['Nekoui|Alireza|A|', 'Blaise|Gilbert|G|']
D000818:Animals D002318:Cardiovascular Diseases D003071:Cognition D003920:Diabetes Mellitus D004921:Erythropoietin D006801:Humans D007668:Kidney D008568:Memory D018919:Neovascularization, Physiologic D019636:Neurodegenerative Diseases D018696:Neuroprotective Agents D009765:Obesity D012160:Retina
Erythropoietin Nonhematopoietic Antiapoptosis Hypoxia-inducible factor Tissue protection